Evidence map›Paper›PMID 41087642›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma.

Minghe Lv, Lei Tang, Liu Yang, Jingping Yu, Qing Ji, Ruping Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Minghe Lv *Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. 17211270006@fudan.edu.cn.ORCID http://orcid.org/0000-0001-9342-773X
Lei TangDepartment of Medical Oncology and Cancer Institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Liu YangDepartment of Oncology, Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Jingping YuDepartment of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Qing Ji *Department of Medical Oncology and Cancer Institute, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Ruping Zhao *Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Funding

National Natural Science Foundation of China 82274338Science and technology development project of Shanghai University of Traditional Chinese Medicine 24KFL065the Shanghai Health Commission 202340160
6 · The paper itself

Abstract

backgroundCisplatin (CDDP) resistance represents an urgent clinical challenge. Identifying CDDP-resistant lung adenocarcinoma (LUAD) patients responsive to immunotherapy through novel biomarkers is critical for improving survival outcomes.

methodsCDDP resistance genes were identified from RNA-seq data of A549 cells in the GEO database. RNA sequencing, genetic mutations, and clinical data of LUAD patients were obtained from TCGA. Patients were split into training and validation cohorts. A prognostic model was developed using LASSO and multivariate Cox regression, with validation in both cohorts. Tumor mutation burden (TMB), immune activity, and functional enrichment analyses (GO, KEGG) were performed to explore the link between lncRNA and CDDP resistance.

resultsTwenty-three CDDP resistance-associated genes were identified from GEO. Co-expression analysis revealed 507 CDDP resistance-linked lncRNAs. Cox regression analysis identified three CDDP resistance-related lncRNAs: ARAP1-AS2, LINC01843, and LINC02198. RT-PCR verified these lncRNAs and representative mRNAs (KIF21B, B3GNT3, PLXNA2). Patients stratified by median risk score showed significantly worse overall survival (OS) and higher mortality in high-risk groups. Univariate/multivariate Cox analyses confirmed the risk score as an independent prognostic factor. A nomogram predicted LUAD survival outcomes. Low-risk patients exhibited significantly lower TMB than high-risk counterparts, with low-risk/high-TMB patients showing optimal OS. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm revealed significant differences in immune dysfunction, CD8

conclusionThese three CDDP resistance-associated lncRNAs including ARAP1-AS2, LINC01843, and LINC02198, serve as reliable prognostic biomarkers for LUAD. The findings provide insights for immunotherapeutic strategies and personalized treatment development.

Indexed as

Adenocarcinoma of LungAntineoplastic AgentsCisplatinDrug Resistance, NeoplasmLung NeoplasmsRNA, Long NoncodingA549 CellsBiomarkers, TumorFemaleHumansMaleMutationPrognosisAntineoplastic AgentsBiomarkers, TumorCisplatinRNA, Long NoncodingCisplatinImmuneLncRNALung adenocarcinomaPrognosisResistance

Identifiers

PMID41087642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.